Why the brepocitinib data matters for Roivant Sciences (ROIV)

The Phase 3 VALOR trial results for brepocitinib in dermatomyositis, published in the New England Journal of Medicine and paired with an FDA Priority Review, put a key Roivant Sciences (ROIV) asset firmly in focus for investors.

Roivant’s recent brepocitinib milestones arrive after a 1 year total shareholder return of 155.49% and a 3 year total shareholder return of 259.35%. The share price, now at US$26.52, shows some near term consolidation after a 22.21% 90 day share price return.

If this kind of biotech catalyst has your attention, it may be worth widening your search to other healthcare names using our screener for 34 healthcare AI stocks.

With the stock up strongly over 1 and 3 years, trading at US$26.52 and sitting about 25% below the average analyst price target, you have to ask: is Roivant still undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 20.2% Undervalued

Roivant’s most followed narrative points to a fair value of $33.25 per share versus the last close at $26.52, putting brepocitinib and the broader pipeline at the center of the story.

Roivant's late-stage pipeline, with potential approvals expected in the next couple of years, could lead to a projected $10 billion+ peak sales portfolio, significantly impacting earnings as these therapies are commercialized.

Curious what kind of revenue ramp, margin shift, and future earnings multiple need to line up to reach that fair value? The narrative leans on aggressive top line growth, a sharp swing in profitability, and a valuation multiple that implies investors are willing to pay up for execution.

Result: Fair Value of $33.25 (UNDERVALUED)

However, you still need to weigh clear execution risk around multiple late stage trials and the unresolved LNP litigation, both of which could derail the current narrative.

Another View: Multiples Paint a Tougher Picture

The popular narrative points to a fair value of $33.25, yet Roivant trades on a P/B of 4.4x versus 2.2x for the US Biotechs industry and 2x for peers. That premium suggests the market already bakes in a lot of success, raising the question of where the real margin of safety lies.

Next Steps

With sentiment clearly leaning optimistic, it makes sense to move quickly and review the underlying data yourself so you are not simply following the crowd. To see what is driving that optimism, review the 2 key rewards

Looking for more investment ideas?

If Roivant is on your radar, do not stop there. A broader watchlist can help you spot opportunities earlier and avoid concentrating on a single story.

• Target potential mispricings by scanning our list of 62 high quality undervalued stocks that pair solid fundamentals with appealing valuations.
• Build a more resilient portfolio by reviewing 64 resilient stocks with low risk scores that score well on financial strength and earnings stability.
• Get ahead of the crowd by checking the screener containing 25 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.